ß-Glucuronidase Producing Bacteria

Your liver spends a lot of energy tagging things for removal. Estrogen you no longer need, drug byproducts, environmental compounds: the liver attaches a sugar-acid handle to each one so it becomes water-soluble and can leave through bile into the gut. Certain gut bacteria carry an enzyme that snips that handle off.

When they do, the compound goes back to its active form, right in the colon, where it can be reabsorbed. This stool test estimates how much of that snipping capacity your gut community carries. It's a research-grade measurement, not a diagnosis, but it maps onto real biology: estrogen recycling, chemotherapy tolerance, and how your colon lining is exposed to reactivated compounds.

What the Test Actually Counts

The assay counts bacterial DNA in your stool, specifically the genes for β-glucuronidase. That's the enzyme that cuts the sugar-acid handle off. Two gene families dominate: one usually called gus or uidA, and a separate family labeled BG. The organisms carrying them come from across the major bacterial groups in the gut, with Bacteroides, Faecalibacterium, Ruminococcus, and Escherichia coli among them.

Here is the important limit, and it shapes everything else on this page. Carrying the gene is not the same as running the enzyme. Some gut E. coli strains carry the gene and still make no working enzyme. Researchers who want to know actual output use a different approach: they add a color-changing substrate to a stool sample and watch how fast it gets cleaved. That's a functional activity assay, and it answers a different question than a gene count does.

The enzyme also comes in many versions. At least 279 distinct bacterial forms have been catalogued in human gut microbiomes, grouped into several structural families. They are not interchangeable. Some cleave small drug molecules quickly; others prefer bulkier targets like steroid hormones. A high total gene count tells you the capacity is there. It does not tell you which substrates your particular community prefers.

Estrogen Recycling

This is the pathway most people come to this test for. Estrone and estradiol leave the liver packaged for excretion. Gut bacteria that unpackage them free the hormone to be reabsorbed, which raises how much estrogen stays in circulation rather than leaving the body. Researchers call the bacterial genes involved the estrobolome.

Higher fecal enzyme activity has been measured in women with polycystic ovary syndrome. In one case-control study, activity ran modestly but significantly higher in the PCOS group, and it tracked positively with blood testosterone. In endometriosis, where uterine-type tissue grows outside the uterus, higher enzyme levels have been measured in women with the condition, and in rodent work giving β-glucuronidase directly made lesions larger and pushed immune cells called macrophages into a state that supports lesion growth. The rodent finding is mechanism, not proof in people.

The direction is not always up. In premature ovarian failure, where the ovaries stop working years early, fecal enzyme activity was markedly lower than in healthy controls, alongside depleted Lactobacillus and Bifidobacterium and lower blood estradiol. So the same marker runs high in one estrogen-related condition and low in another.

And in the condition people worry about most, the signal is thin. Postmenopausal women newly diagnosed with hormone receptor-positive breast cancer carried only slightly more of these bacteria than healthy women, and the difference wasn't statistically significant. Healthy controls in that study ranged from none at all to a third of their gut bacteria.

That apparent contradiction resolves once you stop reading this as a good-number/bad-number test. It measures a recycling capacity, and what that capacity does to you depends on what's in the pipeline. Too much recycling keeps active estrogen in circulation longer, which matters in estrogen-driven conditions. Too little means you're also failing to reclaim useful things, including plant polyphenols and phytoestrogens that arrive at the colon in packaged form and need unpackaging to be absorbed. A very low result is not automatically a clean result.

Chemotherapy Toxicity

This is where the evidence is strongest, and where the mechanism has been proven rather than just observed. Irinotecan, a colorectal cancer drug, is cleared by the liver as an inactive packaged form called SN-38G. Gut bacteria carrying this enzyme cleave it back into active SN-38 inside the colon, where it injures the lining and causes the severe, delayed diarrhea that limits how much drug people can tolerate.

The proof that the bacteria are causing it, not just present for it: small-molecule inhibitors that block the bacterial enzyme protect the gut barrier in animal models without killing the bacteria. Irinotecan treatment itself pushes the community toward enzyme-producing taxa, so the problem compounds as treatment continues. If you are heading into an irinotecan regimen, this is the one setting where knowing your baseline has a clear rationale, though no trial has yet shown that testing changes outcomes.

Colorectal Cancer

In one comparison, fecal enzyme activity ran about 1.7 times higher in people with colon cancer than in healthy controls. The proposed reason is the same reactivation chemistry: carcinogens and other compounds the liver packaged for disposal get unpackaged in the colon, where they sit against the lining.

Read that figure carefully. It comes from a cross-sectional comparison: both groups measured once, at a single point in time. That cannot tell you whether the enzyme came first or the tumor did. There are no prospective cohorts following healthy people to see whether high levels predict later cancer, and no meta-analyses of hard outcomes. A scoping review of this literature concluded that the enzyme's role in colorectal cancer has been studied only retrospectively. This is a plausible mechanism with supportive case-control data, not an established cancer risk marker. Nothing here substitutes for colonoscopy or a stool DNA test.

Inflammatory Bowel Disease

One finding here is unusual enough to be worth knowing. A distinctive cluster of these enzyme genes turned up far more often in Crohn's disease subjects than in controls, and it appeared in unaffected first-degree relatives too. Because it shows up in family members who don't have the disease, it looks more like an inherited feature of the gut community than a consequence of active inflammation. It's a single small case-control study and should be treated as a lead, not a finding to act on.

Why One Reading Can Fool You

Start with the number that matters most for interpreting your own result: in healthy people with no disease at all, the share of gut bacteria carrying these genes ranges from a tiny fraction to most of the community. That is an enormous healthy range, and it overlaps heavily with the range measured in people who do have the associated conditions. A single result sitting high does not put you in a disease group.

Day-to-day noise adds to it. Quantitative profiling of the same people over weeks found that for most gut bacterial genera, the variation within one person exceeded the variation between people, with some genera swinging enormously from one sample to the next. Even with standardized handling, the average genus varied by roughly half its value within a single person. Three things drive much of that short-term swing:

• Stool water content and consistency: a looser or firmer sample shifts measured bacterial proportions independently of any real change in your gut community.
• Transit time: how fast material moves through your colon changes which organisms dominate the sample.
• DNA extraction method: different lab protocols pull different amounts of DNA from different bacteria, which is why results from two labs may not line up.

And the deepest limit is the one already named: this counts genes, not enzyme output. Most of the outcome evidence above, in PCOS, in premature ovarian failure, in colon cancer, comes from activity assays rather than gene counts. High carriage does not reliably predict how much reactivation is actually happening in your colon, because the enzyme variants differ so much in what they'll cleave.

Tracking Your Trend

Given all of that, a single reading is close to uninterpretable on its own. The variability figures above are the argument for trending: if a marker can swing more within one person than it does between people, then only your own repeated pattern tells you anything. Two samples taken a week apart that both land high mean considerably more than one high sample does.

Get a baseline, then repeat in three to six months if you're changing your diet, adding a probiotic, or working on an estrogen-related condition. After that, annually alongside your other gut testing. Sample consistently: same collection method, same lab, and ideally not during a bout of diarrhea or constipation, since stool water content alone moves the number.

A caveat about tracking a supplement's effect. The probiotic evidence here comes from studies measuring gene expression in E. coli and outcomes in mice, not from studies measuring stool gene abundance before and after in people. So if your number drops after starting a probiotic, that's consistent with the mechanism but not the outcome those studies actually measured.

What to Do With an Out-of-Pattern Result

Order the functional activity assay alongside the gene count if you can get it. Gene carriage and enzyme activity are different measurements, and the activity assay answers the question you probably care about: how much cleaving is actually happening. Broader sequencing of your gut community is also worth pairing with this, because it shows whether a high result comes with a loss of butyrate-producing organisms like Faecalibacterium prausnitzii, which is a more meaningful pattern than the enzyme count alone.

Then match your workup to your reason for testing. If estrogen-related symptoms brought you here, pair this with serum estradiol, total testosterone, and sex hormone binding globulin, and take irregular cycles, worsening pelvic pain, or suspected endometriosis to a gynecologist; imaging and endocrine testing diagnose those conditions, not a stool panel. If gut symptoms brought you here, calprotectin and fecal elastase carry more diagnostic weight, and blood in stool or unexplained weight loss means colonoscopy, not more stool profiling. If you're about to start irinotecan, bring this to your oncologist rather than acting on it alone.

What no result here justifies is skipping age-appropriate colorectal screening or self-treating a hormonal condition. A high number is a signal to look at the surrounding picture, not a finding to treat on its own.